Revitalization of Damaged Skin Due to Chronic Skin Diseases

Psoriasis Clinical Trial

Official title:

Revitalization of Damaged Sking Due to Chronic Skin Diseases

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03485560
• Other study ID #: ACEcsd
• Status: Not yet recruiting
• Phase: Early Phase 1
• First received: October 7, 2017
• Last updated: March 26, 2018
• Start date: May 1, 2018
• Est. completion date: January 1, 2019

Study information

• Verified date: November 2017
• Source: Ace Cells Lab Limited
• Contact: Dr. Alaa Abdelkarim MF Mohammed
• Phone: +447473922553
• Email: dralaakarim[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture of natural peptides and herbs. the main aim is to restore the normal skin appearance for the patient and control the episodes of flare.

Description:

Psoriasis is a chronic, immune mediated (type 2 and type 17) chronic skin disease. The production of the immune proteins that leads to continuous inflammatory mediated process. The result of chronic inflammation is they hyper keratotic layer of skin which gets attacks of atopic dermatitis leading to symptoms of itching, pruritis and in situ bleeding.

ACE CSD, with the multiple factors that mediates the immune response and control the protein receptors, in addition to the multiple regeneration peptides that are specifically extracted from healthy skin of newly born sheep; in addition to multiple Chinese herbs that contains different anabolic factors was tested to be able to regenerate the damaged skin and locally modulate the immunity reactions so the skin can regenerate fully to replace the damaged skin with normal healthy skin.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: January 1, 2019
• Est. primary completion date: November 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Chronic skin condition lasts for more than 1 year.

• tried traditional treatment with limited or without effect.

• not on steroids for at least 6 weeks.

Exclusion Criteria:

• patients on steroid.

• patients intolerable to protein or allergic to proteins

• during pregnancy or lactation

Related Conditions & MeSH terms

• Atopic Dermatitis
• Chronic Eczema
• Dermatitis
• Dermatitis, Atopic
• Eczema
• Psoriasis
• Skin Diseases

Intervention

Combination Product:
• ACE CSD
Topical application of the ACE CSD 4 times daily.

Locations

Country	Name	City	State
Serbia	ACE cells Lab Europe Doo	Belgrade
United Kingdom	ACE Cells Lab Limited	Nottingham	Nottinghamshire

Sponsors (1)

Lead Sponsor	Collaborator
Ace Cells Lab Limited

Countries where clinical trial is conducted

Serbia,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Regeneration of the damaged skin lesion	Complete regeneration of the affected skin lesions from the skin disease.	6 - 9 months
Secondary	Flare control	During the attacks of flare, the regenerated skin does not get affected nor show erythematous reaction	1-3 months